Stockscreener 앱 받기
29.09
1.50%
-0.275
전일 마감가:
$29.36
열려 있는:
$29.07
하루 거래량:
361.97K
Relative Volume:
0.08
시가총액:
$2.91B
수익:
-
순이익/손실:
$-99.15M
주가수익비율:
-31.27
EPS:
-0.93
순현금흐름:
$-74.25M
1주 성능:
+11.49%
1개월 성능:
+27.85%
6개월 성능:
-55.25%
1년 성능:
-62.43%
1일 변동 폭
$28.82
$29.63
1주일 범위
$26.57
$30.28
52주 변동 폭
$18.92
$81.86
Viking Therapeutics Inc Stock (VKTX) Company Profile
명칭
Viking Therapeutics Inc
전화
858-704-4660
주소
9920 PACIFIC HEIGHTS BLVD, SUITE 350, SAN DIEGO, CA
VKTX을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VKTX
Viking Therapeutics Inc
|
29.04 | 2.91B | 0 | -99.15M | -74.25M | -0.93 |
|
VRTX
Vertex Pharmaceuticals Inc
|
500.66 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
606.94 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
652.70 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
267.27 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
250.93 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Viking Therapeutics Inc Stock (VKTX) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-04-29 | 개시 | Cantor Fitzgerald | Overweight |
| 2025-04-08 | 개시 | Goldman | Neutral |
| 2025-02-13 | 개시 | Scotiabank | Sector Outperform |
| 2025-02-07 | 개시 | Citigroup | Neutral |
| 2024-12-02 | 개시 | Piper Sandler | Overweight |
| 2024-11-22 | 개시 | B. Riley Securities | Buy |
| 2024-11-04 | 재확인 | H.C. Wainwright | Buy |
| 2024-09-11 | 개시 | JP Morgan | Overweight |
| 2024-06-27 | 개시 | Morgan Stanley | Overweight |
| 2024-05-16 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2024-03-26 | 재확인 | Oppenheimer | Outperform |
| 2024-03-07 | 개시 | Jefferies | Buy |
| 2024-02-28 | 재확인 | Oppenheimer | Outperform |
| 2023-05-31 | 재개 | ROTH MKM | Buy |
| 2023-03-28 | 재확인 | Maxim Group | Buy |
| 2023-03-17 | 개시 | Stifel | Buy |
| 2021-07-29 | 재개 | BTIG Research | Buy |
| 2021-05-25 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2020-06-05 | 개시 | BMO Capital Markets | Outperform |
| 2020-05-05 | 개시 | Chardan Capital Markets | Buy |
| 2020-05-01 | 개시 | BTIG Research | Buy |
| 2019-07-16 | 개시 | Oppenheimer | Outperform |
| 2019-06-25 | 개시 | Stifel | Buy |
| 2019-03-29 | 업그레이드 | SVB Leerink | Mkt Perform → Outperform |
| 2019-03-14 | 재확인 | Maxim Group | Buy |
| 2019-02-22 | 개시 | SVB Leerink | Mkt Perform |
| 2018-12-12 | 개시 | B. Riley FBR | Buy |
| 2018-11-19 | 업그레이드 | Raymond James | Outperform → Strong Buy |
| 2018-09-18 | 재확인 | H.C. Wainwright | Buy |
| 2018-09-18 | 재확인 | Maxim Group | Buy |
| 2018-09-18 | 재확인 | Raymond James | Outperform |
| 2018-07-20 | 개시 | SunTrust | Buy |
| 2018-06-28 | 개시 | Raymond James | Outperform |
| 2018-06-01 | 재확인 | Laidlaw | Buy |
| 2018-05-31 | 재확인 | Maxim Group | Buy |
| 2018-03-26 | 재개 | H.C. Wainwright | Buy |
| 2017-11-28 | 재확인 | Maxim Group | Buy |
| 2017-11-21 | 개시 | ROTH Capital | Buy |
모두보기
Viking Therapeutics Inc 주식(VKTX)의 최신 뉴스
Why Viking Therapeutics Stock Was Victorious This Week - MSN
(VKTX) Investment Report - news.stocktradersdaily.com
Viking Therapeutics (VKTX) Sees 20% Stock Surge Despite Financial Losses - GuruFocus
Why Viking Therapeutics (VKTX) Stock is Rising Today - GuruFocus
Viking Therapeutics call volume above normal and directionally bullish - TipRanks
Viking Therapeutics (VKTX) Sees Surge in Call Options Trading | VKTX Stock News - GuruFocus
Viking Therapeutics (NasdaqCM:VKTX) Reports Increased Net Loss of US$46 Million in Q1 2025 - simplywall.st
Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday - The Globe and Mail
This Soaring Stock Just Delivered More Good News. Time to Buy? - AOL.com
Where Will Viking Therapeutics Be in 3 Years? - Nasdaq
1 Beaten-Down Stock to Buy and Hold for 10 Years - Yahoo Finance
BlackRock, Inc. Reduces Stake in Viking Therapeutics Inc - GuruFocus
Viking Therapeutics (VKTX) Sees Boost After Pfizer's Acquisition Plans - GuruFocus
Will Pfizer Acquire Altimmune or Viking Therapeutics After Its Obesity Pill Setback? - Yahoo Finance
Prediction: Pfizer's Loss May Be Viking Therapeutics' Gain - The Motley Fool
Viking stock rises as Pfizer ups deal prospects (VKTX:NASDAQ) - Seeking Alpha
Why Viking Therapeutics Stock Popped Again Today - MSN
VKTX Stock Surges Amid Analyst Optimism on VK2735 - GuruFocus
Cantor Fitzgerald starts Viking Therapeutics stock with Overweight By Investing.com - Investing.com India
Cantor Fitzgerald starts Viking Therapeutics stock with Overweight - Investing.com
Cantor Fitzgerald initiated coverage on Viking Therapeutics with a new price target - Quantisnow
Why Viking Therapeutics (VKTX) Stock is On the Move - GuruFocus
Viking Therapeutics (VKTX) Sees Stock Rise Despite Increased Los - GuruFocus
Viking Therapeutics (VKTX) Gains Overweight Rating from Cantor F - GuruFocus
Why Viking Therapeutics Stock Popped Today - MSN
Viking Therapeutics (VKTX) Price Target Reduced Amid Competitive Obesity Market | VKTX Stock News - GuruFocus
Viking Therapeutics price target lowered to $75 from $95 at Truist - TipRanks
Decoding Viking Therapeutics Inc (VKTX): A Strategic SWOT Insigh - GuruFocus
Viking Therapeutics Q1 Loss Wider Than Expected, Sales Nil, Stock Dips - MSN
Viking Therapeutics targets 2025 Phase 3 trials for VK2735 obesity program with promising results - MSN
Press Release Distribution & PR Platform - ACCESS Newswire
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Viking Therapeutics EPS Miss Overlooked as Long-Term Pipeline Gains Focus - Investing.com
Viking Therapeutics Stock May Struggle After As-Expected Report - MarketBeat
Viking Therapeutics, Inc. SEC 10-Q Report - TradingView
Viking Therapeutics (NasdaqCM:VKTX) Reports Increased Net Loss for Q1 2025 - simplywall.st
Viking Therapeutics (VKTX) Price Target Reduced by B. Riley | VKTX Stock News - GuruFocus
Viking Therapeutics Inc (VKTX) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Rising ... - Yahoo Finance
Viking Therapeutics Inc (VKTX) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Rising Expenses - GuruFocus
Viking Therapeutics Inc (VKTX) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Rising ... By GuruFocus - Investing.com Canada
Viking Therapeutics (VKTX) Eyes Takeover Amid Rumors - GuruFocus
Viking Therapeutics Advances Clinical Pipeline in Q1 2025 - TipRanks
Earnings call transcript: Viking Therapeutics Q1 2025 misses EPS forecast - Investing.com
Viking Therapeutics Inc (VKTX) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Viking Therapeutics Inc 주식 (VKTX) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Rouan Sarah Kathryn | Director |
Mar 31 '25 |
Buy |
24.15 |
1,240 |
29,943 |
1,240 |
| Lian Brian | President & CEO |
Jan 06 '25 |
Sale |
42.75 |
194,490 |
8,313,601 |
2,366,570 |
| Mancini Marianna | Chief Operating Officer |
Jan 06 '25 |
Sale |
42.75 |
54,215 |
2,317,599 |
374,134 |
| ZANTE GREG | Chief Financial Officer |
Jan 06 '25 |
Sale |
42.75 |
50,309 |
2,150,595 |
165,259 |
0.70%
3.92%
자본화:
|
볼륨(24시간):